phase III fully recruited as of 11/09; expected BLA submission by spring 2011 (2/10)
Brand Diamyd, Ortho-McNeil-Janssen Generic GAD65 vaccine
Company name Diamyd Product type Speciality
Therapeutic category Immunologic agents Key uses diabetes, Type I
Other Uses latent autoimmune diabetes in adults (LADA) Drug Class vaccine
Dosage From SC Expected Approval 2011-Q4
FDA Filing N/A Last Update date June 23,2010
Link to pipeline report
Link to news article
Link to clinicaltrials.gov